NDA 020753 · Pfizer
Aromasin
Exemestane · Oral · Aromatase Inhibitor
NovelOrphanLast checked: Nov 19, 2026Latest source record: Dec 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Oct 21, 1999
Approved uses
3
Original approval plus efficacy supplements
Registered trials
344
100 Phase 3, 56 recruiting
FAERS reports
21,520
16,483 serious, 2,534 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 24, 2025.
EXEMESTANE is an aromatase inhibitor indicated for: • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to EXEMESTANE for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). • treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women EXEMESTANE is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to EXEMESTANE for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ]. 1.2 Advanced Breast Cancer in Postmenopausal Women EXEMESTANE is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ].
Mechanism: Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 25, 2016 Supplement 18 · Efficacy LabelLetter
- Oct 5, 2005 Supplement 6 · Efficacy LabelLetter
- Oct 21, 1999 Original approval · Type 1 - New Molecular Entity LabelReviewLetter
1 products under this application
- AROMASIN · EXEMESTANE 25MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Exemestane" as an intervention, any sponsor and status, largest first.
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)Pivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT00310180 · 10,273 participants · Start Apr 7, 2006 · Primary completion Mar 2, 2018
Drug: Anastrozole; Exemestane and 2 more · For: Breast Adenocarcinoma; Hormone Receptor Positive; Stage IA Breast Cancer AJCC v7 and 4 more
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 1,222 sites in all
- Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast CancerPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00279448 · 9,779 participants · Start Jan 2002 · Primary completion Nov 2008
Drug: exemestane; tamoxifen · For: Breast Neoplasms
Sites: Marseille, France; Compiègne, France; Rennes, France · 59 sites in all
- Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By ExemestanePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00036270 · 9,779 participants · Start Aug 2001 · Primary completion Oct 2008
Drug: exemestane (Aromasin); tamoxifen + exemestane · For: Breast Neoplasms
Sites: Bessemer, Alabama; Birmingham, Alabama; Flagstaff, Arizona · 179 sites in all
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05514054 · 8,000 participants (planned) · Start Oct 4, 2022 · Primary completion Oct 2027
Drug: Imlunestrant; Tamoxifen and 3 more · For: Breast Neoplasms
Sites: Daphne, Alabama; Huntsville, Alabama; Mobile, Alabama · 672 sites in all
- Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast CancerPivotal-lookingCompleted
NCIC Clinical Trials GroupResearch network
NCT00066573 · 7,576 participants · Start Jun 6, 2003 · Primary completion Nov 7, 2010
Drug: anastrozole; exemestane · For: Breast Cancer
Sites: Calgary, Canada; Lethbridge, Canada; Kelowna, Canada · 39 sites in all
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05952557 · 5,511 participants · Start Oct 5, 2023 · Primary completion Mar 4, 2030
Drug: Camizestrant; Tamoxifen and 4 more · For: Breast Cancer, Early Breast Cancer
Sites: Dothan, Alabama; Phoenix, Arizona; Tucson, Arizona · 661 sites in all
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast CancerPivotal-lookingRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07349069 · 5,500 participants (planned) · Start Mar 4, 2026 · Primary completion Dec 2030
Drug: HRS-8080 Tablets; Letrozole tablets and 3 more · For: Breast Cancer
Sites: Nanjing, China; Shanghai, China
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT01272037 · 5,018 participants · Start Feb 28, 2011 · Primary completion Feb 1, 2023
Drug: Anastrozole; Exemestane and 3 more · For: Breast Ductal Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma and 2 more
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 1,568 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue2,281
- malignant neoplasm progression1,832
- nausea1,749
- arthralgia1,747
- diarrhoea1,732
- dyspnoea1,412
- pain1,146
- asthenia1,105
- headache1,100
- malaise1,086
- cough1,042
- vomiting1,009
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 99 |
| 2005 | 234 |
| 2006 | 253 |
| 2007 | 256 |
| 2008 | 337 |
| 2009 | 378 |
| 2010 | 588 |
| 2011 | 521 |
| 2012 | 618 |
| 2013 | 930 |
| 2014 | 1,022 |
| 2015 | 1,753 |
| 2016 | 1,763 |
| 2017 | 1,454 |
| 2018 | 1,444 |
| 2019 | 1,716 |
| 2020 | 1,594 |
| 2021 | 1,257 |
| 2022 | 1,303 |
| 2023 | 1,281 |
| 2024 | 1,089 |
| 2025 | 1,001 |
| 2026 | 628 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Aromasin (Exemestane)
2024 spending
$1.2M
Beneficiaries
116
646 claims
Per beneficiary
$10,045
$36.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,358,708 |
| 2021 | $1,845,636 |
| 2022 | $1,290,233 |
| 2023 | $1,352,024 |
| 2024 | $1,165,163 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.
Jhaveri KL, Neven P, Casalnuovo ML, et al. · Ann Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Adjuvant ovarian suppression in premenopausal breast cancer.
Francis PA, Regan MM, Fleming GF, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Multicenter Study
- Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
Pagani O, Walley BA, Fleming GF, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
Kalinsky K, Accordino MK, Chiuzan C, et al. · J Clin Oncol 2023 · Clinical Trial, Phase II, Randomized Controlled Trial
- Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Baselga J, Campone M, Piccart M, et al. · N Engl J Med 2012 · Clinical Trial, Phase III, Comparative Study
- Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, et al. · Lancet Oncol 2022 · Randomized Controlled Trial, Multicenter Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.